Vasopressin and Water Regulation

Mechanism of Action

Vasopressin increases water reabsorption in the kidney collecting ducts by triggering the insertion of aquaporin water channels into the luminal membrane, allowing water to flow from the tubule lumen to the hypertonic medullary interstitium, resulting in concentrated urine with osmolality typically >300 mOsm/kg H₂O 1
The binding of vasopressin to V2 receptors on the basolateral membrane of collecting duct cells initiates a cascade involving G-protein activation, adenylyl cyclase activation, cAMP production, and protein kinase A stimulation, resulting in the exocytic insertion of aquaporin-2 (AQP2) water channels into the luminal membrane 1
Water then flows through AQP2 in the apical membrane and through constitutive water channels (AQP3 and AQP4) in the basolateral membrane, enabling the formation of concentrated urine 1

Vasopressin exerts its effects through different receptor subtypes, including V1a receptors, which mediate vasoconstriction, and V2 receptors, which mediate antidiuretic effects, according to the Intensive Care Medicine guidelines 2
V1a receptors are primarily located on vascular smooth muscle cells and in the myocardium, mediating vasoconstriction effects of vasopressin, as stated in the Intensive Care Medicine guidelines 2, 3
V2 receptors are predominantly found in the kidney, specifically localized to collecting ducts and medullary tubules, mediating anti-diuretic effects of vasopressin, as described in the Nature Reviews Nephrology guidelines 1, 3

In congenital nephrogenic diabetes insipidus, there is resistance to vasopressin action due to mutations in either the V2 receptor (AVPR2) or the AQP2 gene, resulting in inability to concentrate urine, with urine osmolality usually <200 mOsm/kg H₂O, and patients present with polyuria, polydipsia, and risk of dehydration 1
Vasopressin analogues should be avoided in patients with autosomal dominant polycystic kidney disease (ADPKD) as they may accelerate cyst growth 4
In heart failure, vasopressin activation contributes to salt and water retention, potentially worsening congestion, and V2 receptor antagonists like tolvaptan are used for treating hyponatremia associated with heart failure, cirrhosis, and SIADH 5, 6
Desmopressin, a synthetic vasopressin analog, is used as replacement therapy for central diabetes insipidus, characterized by polyuria and polydipsia, as described in the Nature Reviews Nephrology guidelines 1

The use of vasopressin (0.01-0.04 units/min) for septic shock and other types of vasodilatory shock is recommended, as stated in the Intensive Care Medicine guidelines 2
Overdosage of vasopressin can lead to water retention and hyponatremia, and elderly patients and those with renal impairment require careful dosing and monitoring, as stated in the Intensive Care Medicine guidelines 2
Vasopressin is contraindicated in moderate to severe renal impairment (creatinine clearance <50 mL/min), according to the Intensive Care Medicine guidelines 2

The potential mechanisms by which vasopressin may contribute to chronic kidney disease progression include effects on mesangial cell proliferation, renin secretion, renal hemodynamics, and blood pressure, although the strength of evidence for these mechanisms is not provided 1
Understanding the distribution and function of V1a and V2 receptors is crucial for developing targeted therapies for conditions like hyponatremia, heart failure, and septic shock, as stated in the Nature Reviews Nephrology guidelines and the Intensive Care Medicine guidelines 3, 1